---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026162"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:22:51.133586+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns

## Summary
- Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.
- Amy Burroughs appointed Class II director, term expiring at 2023 annual meeting.
- Burroughs receives annual cash retainer of $35,000 plus $7,500 for audit committee; granted option for 40,000 shares vesting monthly over 3 years.
- Burroughs is President & CEO of Cleave Therapeutics, brings >20 years healthcare/biotech experience.

## SEC filing metadata
- accession: 0000950170-22-026162
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/tnya-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026162
- JSON: https://secwatch.observer/filing/0000950170-22-026162.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026162.txt

## Key facts
- Executive change
  Eli Casdin resigned as Director at Tenaya Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm
- Executive change
  Amy Burroughs was appointed as Class II Director at Tenaya Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.